<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8401784</journal-id>
<journal-id journal-id-type="pubmed-jr-id">99</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Dev Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int. J. Dev. Neurosci.</journal-id>
<journal-title-group>
<journal-title>International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0736-5748</issn>
<issn pub-type="epub">1873-474X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28610974</article-id>
<article-id pub-id-type="pmc">5563212</article-id>
<article-id pub-id-type="doi">10.1016/j.ijdevneu.2017.06.001</article-id>
<article-id pub-id-type="manuscript">NIHMS884898</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Positive modulation of α5 GABA<sub>A</sub> receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Batinić</surname>
<given-names>Bojan</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Santrač</surname>
<given-names>Anja</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jančić</surname>
<given-names>Ivan</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Guanguan</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vidojević</surname>
<given-names>Aleksandra</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marković</surname>
<given-names>Bojan</given-names>
</name>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cook</surname>
<given-names>James M.</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Savić</surname>
<given-names>Miroslav M.</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>a</label>Department of Physiology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia</aff>
<aff id="A2">
<label>b</label>Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia</aff>
<aff id="A3">
<label>c</label>Department of Microbiology and Immunology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia</aff>
<aff id="A4">
<label>d</label>Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee and the Milwaukee Institute of Drug Discovery, P.O.Box413, Milwaukee, WI 53201, USA</aff>
<aff id="A5">
<label>e</label>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author: Dr Miroslav M. Savić, Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia, Tel.:+381-11-3951280, Fax: +381-11-3972840, <email>miroslav@pharmacy.bg.ac.rs</email> (M. M. Savić)</corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Conflict of interest</bold>
</p>
<p>We declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>15</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>61</volume>
<fpage>31</fpage>
<lpage>39</lpage>
<!--elocation-id from pubmed: 10.1016/j.ijdevneu.2017.06.001-->
<abstract id="Abs1">
<p id="P2">We previously demonstrated that lipopolysaccharide (LPS) administered intraperitoneally (i.p.) to pregnant Wistar rat dams, at embryonic days 15 and 16 (E15/16), induced a decrease of baseline locomotor activity and diminished reactivity to amphetamine in adult female offspring. In the present study we aimed to assess the duration of LPS-induced maternal immune activation (MIA) and investigate possible changes in levels of main neurotransmitters in fetal brain during MIA. We hypothesized that the observed behavioral changes may be linked with MIA-induced disturbance of prenatal GABAergic system development, especially with α5 GABA<sub>A</sub> receptors (α5GABA<sub>A</sub>Rs), expression of which takes place between E14 and E17. Thereafter, we set to investigate if later potentiation of α5GABA<sub>A</sub>Rs in offspring’s preadolescence (from postnatal day 22 to 28) could prevent the deficit in locomotor reactivity to amphetamine observed in adulthood, at postnatal day P60. The elevation of IL-6 in amniotic fluid 6 h after LPS treatment (100 μg/kg, i.p.) at E15 was concurrent with a significant increase of GABA and decrease of glutamate concentration in fetal brain. Moreover, repeated administration of MP-III-022, a selective positive allosteric modulator of α5GABA<sub>A</sub>Rs, at a dose (2 mg/kg daily, i.p.) derived from a separate pharmacokinetic study, prevented the LPS-induced decrease in locomotor reactivity to amphetamine (0.5 mg/kg, i.p.) in adult females. These results were not mirrored in the parallel set of experiments with male offspring from LPS-treated rats. The results suggest that pharmacological potentiation of α5GABA<sub>A</sub>Rs activity in preadolescence may ameliorate at least some of adverse consequences of exposure to MIA <italic>in utero</italic>.</p>
</abstract>
<abstract abstract-type="graphical" id="Abs2">
<title>Graphical Abstract</title>
<p id="P3">
<graphic orientation="portrait" position="anchor" xlink:href="nihms884898u1.jpg"></graphic></p>
</abstract>
<kwd-group>
<kwd>MP-III-022</kwd>
<kwd>neurochemistry</kwd>
<kwd>pharmacokinetic profile</kwd>
<kwd>cytokines</kwd>
<kwd>preadolecence</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>